Breaks Categories: Stock Spotlights

FridayJan 27, 2017 12:15 pm

NetworkNewsBreaks – Novan, Inc. (NASDAQ: NOVN) Shares Plunge on Inconsistent Topline Results from SB204 Phase 3 Pivotal Trials

Novan (NASDAQ: NOVN) shares dropped 75% this morning following the release of top-line results from the two, replicate phase 3 pivotal clinical trials for the company’s topical nitric oxide-releasing product candidate SB204 in the treatment of acne vulgaris. In the intent-to-treat analysis, SB204 demonstrated statistical significance on all three co-primary endpoints in NI-AC302, but it demonstrated statistical significance on only one of three co-primary endpoints in NI-AC301. The three co-primary endpoints included the absolute changes in inflammatory and non-inflammatory lesion counts and proportion of patients achieving success, “clear” or “almost clear,” on the Investigator Global Assessment (IGA) at week 12. …

Continue Reading

ThursdayJan 26, 2017 1:36 pm

NetworkNewsBreaks – Gopher Protocol, Inc. (GOPH) Competes in $1B GPS Personal Tracking Industry with Innovative GuardianPatch

Gopher Protocol (OTCQB: GOPH) develops real-time, self-learning (heuristic) mobile technologies. In collaboration with partner Guardian Patch LLC, Gopher has developed Guardian Patch Location Technology. The company’s patented Integrated Circuit (IC) GopherInsight technology is part of the muscle behind the mobile app designed to track valuables such as electronics or other objects, loved ones or even pets. In November 2016, the GuardianPatch patent was finalized and filed. The product is expected to hit the market in 2017, aligned with the current boom in GPS personal tracking devices and applications, a market expected to break $1 billion in 2017. To learn more,…

Continue Reading

ThursdayJan 26, 2017 1:34 pm

NetworkNewsBreaks – Kindred Biosciences, Inc.’s (NASDAQ: KIN) Strategy to Capture its Share of $7.5B Animal Health Market

Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company taking aim at the $7.5 billion animal health market, specifically focusing on therapies for pets. The company has established a simple, yet effective, strategy to capture its share of the market: leverage investments made in human pharmaceutical R&D to develop therapies that offer the benefits of lower risk, lower cost, and shorter time-to-market. Kindred currently has in development an exciting pipeline of more than 20 programs of high-value products for dogs, cats and horses. The company’s lead candidates are Mirataz™, a weight loss product for cats, and Zimeta™ to treat fever…

Continue Reading

ThursdayJan 26, 2017 1:26 pm

NetworkNewsBreaks – Regulatory Approvals Mark Significant Milestones for Trendlines Group Ltd.’s (TRNLY) Gordian Surgical

Gordian Surgical, a medical portfolio company of Trendlines Group Ltd. (OTCQX: TRNLY), is making significant advances in the way surgical procedures are performed with its TroClose1200™, which in the fourth quarter of 2016 was awarded both U.S. FDA regulatory clearance and CE Mark certification. TroClose1200 was designed to provide surgeons "two-in-one" functionality. The device acts as a trocar, through which surgical instruments enter the abdomen; and as a device to close internal incisions made during surgery. It works by enabling the insertion of sutures into the tissue at the beginning of the procedure and is anchored to remain in place…

Continue Reading

ThursdayJan 26, 2017 1:20 pm

NetworkNewsBreaks – Asterias Biotherapeutics (NYSE: AST): AST-OPC1 Efficacy Results Demonstrate Life-changing Potential for Spinal Cord Injury Patients

With an eye on FDA discussions later this year, biotech Asterias (NYSE: AST) is harnessing the potential of regenerative medicine to improve the quality of life of patients with spinal cord injuries (SCI). Recent efficacy results from the ongoing phase 1/2a clinical trial showed that SCI patients treated with the company’s AST-OPC1 cells demonstrated improved ability to use their arms, hands and fingers. Company CEO Steve Cartt in a press release called the results encouraging as Asterias plans for discussions with the FDA in mid-2017 to determine the appropriate strategy for regulatory approval. According to the World Health Organization, between…

Continue Reading

ThursdayJan 26, 2017 1:17 pm

NetworkNewsBreaks – Fuwei Films (NASDAQ: FFHL) Shares Surge on Potential of New Polyester Film Sales Contract

Shares of Fuwei Films (NASDAQ: FFHL) are up 54% this morning on news the company has signed an annual sales contract with Eternal Electronic Material (Guangzhou) Co., Ltd., an existing costumer that purchases polyester film for printed circuit boards (PCB). Fuwei expects that the new contract for 2017 will increase the total polyester film for PCB sales in the first quarter of the year by approximately 34.5% compared to the same period of 2016. "Our company will continue to execute a portfolio of products that optimizes a higher margin strategy. We intend to continue to leverage our R&D capabilities and…

Continue Reading

WednesdayJan 25, 2017 1:36 pm

NetworkNewsBreaks – Advantage Lithium (AVLIF) Tackles Growing Lithium Demand with Strongest Drill Results to Date

Advantage Lithium (OTCQB: AVLIF) is a lithium explorer and developer with an international portfolio of quality assets. The company wrapped up 2016 with results from its Clayton NE project, in which the company drilled lithium brines on all three of its drill holes in the Clayton Valley, Nevada. Lithium brines intercepted by the third drill hole demonstrated the strongest results to date, showing peak values of 322 mg/l lithium. According to the company, the demand for lithium is growing rapidly with predicted growth to triple over the next 10 years, and it already exceeds supply by 15%. The increasing battery…

Continue Reading

WednesdayJan 25, 2017 12:28 pm

NetworkNewsBreaks – GSI Technology, Inc. (NASDAQ: GSIT) Targets High-Performance Memory Market and In-Place Associative Compute Market

GSI Technology (NASDAQ: GSIT) historically designs, develops and markets high-performance memory products primarily for networking and telecommunication equipment manufacturers, in a market currently estimated at $500 million.  More recently, it has expanded its development strategy to include RadHard SRAM targeted at aerospace and defense applications and a patented in-place associative compute solution for applications such as machine learning, image detection, speech recognition, recommender systems for e-commerce, data mining, and cyber security, a booming market with huge growth potential over the next decade and beyond.  GSI is primed to capitalize on the many opportunities afforded to it by its patented in-place…

Continue Reading

WednesdayJan 25, 2017 12:23 pm

NetworkNewsBreaks – Akebia Therapeutics, Inc. (NASDAQ: AKBA) Remains Focused on Further Development of Vadadustat

Akebia Therapeutics (NASDAQ: AKBA) is a biopharmaceutical company engaged in discovering and developing novel therapeutic solutions that leverage hypoxia inducible factor (HIF) biology, a primary regulator involved in multiple major biological pathways. According to an earlier Aegis report (http://nnw.fm/F4ezY), Akebia’s lead product candidate, vadadustat, has an impressive 60 percent probability of clinical success. Vadadustat is currently in phase III trials, after encouraging results were reported during phase II testing. In December 2016, Akebia signed a collaboration and license agreement with Otsuka Pharmaceutical (OTC: OTSKF) for vadadustat in the U.S. The companies will equally share the revenue and commercialization costs of…

Continue Reading

WednesdayJan 25, 2017 10:29 am

NetworkNewsBreaks – Breaking News: Dow Rockets above 20,000, Clinches Milestone under Trump Administration

No matter your view on President Trump, there’s no arguing his initial influence on the markets. The Dow Jones Industrial Average (DJIA) this morning jumped more than 100 points to cross the 20,000 mark for the first time in its 120-year history. The rally comes despite a flurry of controversy as the new Administration sets the pen to abortion, illegal voting, a border wall, and other social issues. While CNBC’s Jim Cramer recently discussed how President Trump’s plan to cut taxes would grow the economy, the Dow’s milestone could also reflect economic solidarity and recent jobs report attributed to former…

Continue Reading